Evidence map›Paper›PMID 38329708›Full record

ReviewPurinergic signalling2025

Targeting adenosine A

Xuhao Chen, Xiaoting Sun, Yuanyuan Ge, Xuzhao Zhou, Jiang-Fan Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuhao ChenThe Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.
Xiaoting SunThe Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.
Yuanyuan GeThe Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.
Xuzhao ZhouThe Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China. zhouxuzhao@wmu.edu.cn.
Jiang-Fan ChenThe Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China. chenjf555@gmail.com.

Funding

Key Research Project from Zhejiang Provincial Administration of Science & Technology, and the Natural Science Foundation of Zhejiang Province of China 2023C03079Key Research Project from Zhejiang Provincial Administration of Science & Technology, and the Natural Science Foundation of Zhejiang Province of China LQ22H090013National Natural Science Foundation of China 82101556National Natural Science Foundation of China 82151308Pro-gram Project from the State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University J01-20190101Research Fund for International Senior Scientists 82150710558Start-up Fund from the Oujiang Laboratory OJQDSP2022007
6 · The paper itself

Abstract

Retinopathy of prematurity (ROP) continues to pose a significant threat to the vision of numerous children worldwide, primarily owing to the increased survival rates of premature infants. The pathologies of ROP are mainly linked to impaired vascularization as a result of hyperoxia, leading to subsequent neovascularization. Existing treatments, including anti-vascular endothelial growth factor (VEGF) therapies, have thus far been limited to addressing pathological angiogenesis at advanced ROP stages, inevitably leading to adverse side effects. Intervention to promote physiological angiogenesis during the initial stages could hold the potential to prevent ROP. Adenosine A

Indexed as

Adenosine A2 Receptor AntagonistsReceptor, Adenosine A2ARetinopathy of PrematurityAnimalsHumansInfant, NewbornAdenosine A2 Receptor AntagonistsReceptor, Adenosine A2AAdenosine A2A receptorsAngiogenesisCell proliferationOxygen-induced retinopathyRetinopathy of prematurity

Identifiers

PMID38329708
PMCPMC12454231

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.